These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 11535969

  • 1. [Use of clodronic acid in mineral metabolism conditions: state of the art in 2000].
    Brandi ML.
    Minerva Med; 2001 Aug; 92(4):251-68. PubMed ID: 11535969
    [Abstract] [Full Text] [Related]

  • 2. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders.
    Ghinoi V, Brandi ML.
    Expert Opin Pharmacother; 2002 Nov; 3(11):1643-56. PubMed ID: 12437497
    [Abstract] [Full Text] [Related]

  • 3. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M, Balducci S, Schiappoli A, Caliumi C, Petramala L, Cerci S, Cotesta D, D'Erasmo E, Letizia C.
    Ann Ital Med Int; 2003 Nov; 18(2):89-98. PubMed ID: 12886826
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clodronate treatment of established bone loss in cardiac recipients: a randomized study.
    Ippoliti G, Pellegrini C, Campana C, Rinaldi M, D'Armini A, Goggi C, Aiello M, Viganò M.
    Transplantation; 2003 Feb 15; 75(3):330-4. PubMed ID: 12589153
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Strontium ranelate: a novel concept for the treatment of osteoporosis].
    Dimai HP.
    Wien Klin Wochenschr; 2005 Nov 15; 117(21-22):728-38. PubMed ID: 16416353
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Diphosphonates in the treatment of bone metastases].
    Jung A, Fleisch H.
    Schweiz Med Wochenschr; 1981 Dec 05; 111(49):1878-82. PubMed ID: 6460313
    [Abstract] [Full Text] [Related]

  • 14. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
    D'Amelio P, Muratore M, Tinelli F, Tamone C, Cosentino L, Quarta E, Calcagnile F, Carlo Isaia G.
    Int J Tissue React; 2003 Dec 05; 25(2):73-8. PubMed ID: 14518596
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May 05; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 17. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun 05; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 18. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr 05; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb 05; 14(75):5-9. PubMed ID: 15747448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.